Bria-IMT™ Cell Therapy
Latest Developments
BriaCell Pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer is ongoing
The pivotal Phase 3 combination study is listed on ClinicalTrials.gov as NCT06072612.
Bria-IMT™ was awarded Fast Track status by the U.S. Food and Drug Administration (FDA).
About Bria-IMT™ (SV-BR-1-GM)
Developed and characterized by a team of dedicated scientists and clinicians, Bria-IMT™ (SV-BR-1-GM) is an off-the-shelf targeted cell-based immunotherapy for the treatment of metastatic breast cancer (i.e. breast cancer that has spread from the breast or armpit to other areas of the body including the bones, lungs, liver or sometimes the brain). Bria-IMT™ is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted immunotherapy.
Mechanism of Action of Bria-IMT™: The mechanism of action of Bria-IMT™ is currently under investigation. We hypothesize that Bria-IMT™ both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. INDIRECTLY, Bria-IMT™ produces multiple breast cancer “antigens” (proteins that are expressed in breast cancer cells) that are identified by the patient’s immune system. Some of these same antigens are expressed by a patient’s breast cancer and are recognized by the immune system which activates antigen specific tumor killing cells. In addition, Bria-IMT™ appears to be able to DIRECTLY stimulate these cancer-fighting immune cells markedly, further boosting the body’s immune cell response.
We believe that Bria-IMT™:
-
1. Produces antigens (proteins made by breast cancer cells) which are taken up by immune cells.
2. The immune cells present the antigens to CD4+ and CD8+ T-cells, cells known for tumor destruction.
3. Secretes a protein called GM-CSF which further boosts the immune response.
4. Also directly stimulates cancer-fighting T-cells, acting like an immune cell, further boosting the immune cell’s response.